Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Rapid Emergence, Subsidence, and Molecular Detection of Escherichia coli Sequence Type 1193-fimH64, a New Disseminated Multidrug-Resistant Commensal and Extraintestinal Pathogen.

Johnson JR, Johnston BD, Porter SB, Clabots C, Bender TL, Thuras P, Trott DJ, Cobbold R, Mollinger J, Ferrieri P, Drawz S, Banerjee R.

J Clin Microbiol. 2019 Apr 26;57(5). pii: e01664-18. doi: 10.1128/JCM.01664-18. Print 2019 May.

PMID:
30787145
2.

Variation in resistance traits, phylogenetic backgrounds, and virulence genotypes among Escherichia coli clinical isolates from adjacent hospital campuses serving distinct patient populations.

Drawz SM, Porter S, Kuskowski MA, Johnston B, Clabots C, Kline S, Ferrieri P, Johnson JR.

Antimicrob Agents Chemother. 2015 Sep;59(9):5331-9. doi: 10.1128/AAC.00048-15. Epub 2015 Jun 22.

3.
4.

Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.

Drawz SM, Marschner S, Yañez M, García de Coca A, Feys HB, Deeren D, Coene J.

Transfusion. 2015 Jul;55(7):1745-51. doi: 10.1111/trf.13026. Epub 2015 Feb 23.

PMID:
25702711
5.

Early diagnosis of intravascular large B-cell lymphoma: clues from routine blood smear morphologic findings.

Patel SS, Aasen GA, Dolan MM, Linden MA, McKenna RW, Rudrapatna VK, Trottier BJ, Drawz SM.

Lab Med. 2014 Summer;45(3):248-52; quiz e93. doi: 10.1309/LMSVEOKLN18M5XTV.

PMID:
25051078
6.

Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance.

Watkins RR, Papp-Wallace KM, Drawz SM, Bonomo RA.

Front Microbiol. 2013 Dec 24;4:392. doi: 10.3389/fmicb.2013.00392.

7.

New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Drawz SM, Papp-Wallace KM, Bonomo RA.

Antimicrob Agents Chemother. 2014;58(4):1835-46. doi: 10.1128/AAC.00826-13. Epub 2013 Dec 30. Review.

8.

Pokes, pathogens, and primum non nocere: prudent prophylaxis protocols for prostate biopsy.

Drawz SM, Johnson JR.

Infect Control Hosp Epidemiol. 2013 Sep;34(9):977-9. doi: 10.1086/671937. Epub 2013 Jul 26. No abstract available.

PMID:
23917914
9.

Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans.

Johnson JR, Drawz SM, Porter S, Kuskowski MA.

Antimicrob Agents Chemother. 2013 Oct;57(10):4856-60. doi: 10.1128/AAC.00650-13. Epub 2013 Jul 22.

10.

OxyR contributes to the virulence of a Clonal Group A Escherichia coli strain (O17:K+:H18) in animal models of urinary tract infection, subcutaneous infection, and systemic sepsis.

Johnson JR, Russo TA, Drawz SM, Clabots C, Olson R, Kuskowski MA, Rosen H.

Microb Pathog. 2013 Nov;64:1-5. doi: 10.1016/j.micpath.2013.07.001. Epub 2013 Jul 12.

PMID:
23850958
11.

Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Winkler ML, Rodkey EA, Taracila MA, Drawz SM, Bethel CR, Papp-Wallace KM, Smith KM, Xu Y, Dwulit-Smith JR, Romagnoli C, Caselli E, Prati F, van den Akker F, Bonomo RA.

J Med Chem. 2013 Feb 14;56(3):1084-97. doi: 10.1021/jm301490d. Epub 2013 Feb 4.

12.

Crystal structure of a preacylation complex of the β-lactamase inhibitor sulbactam bound to a sulfenamide bond-containing thiol-β-lactamase.

Rodkey EA, Drawz SM, Sampson JM, Bethel CR, Bonomo RA, van den Akker F.

J Am Chem Soc. 2012 Oct 10;134(40):16798-804. doi: 10.1021/ja3073676. Epub 2012 Sep 26.

13.

Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone.

Papp-Wallace KM, Bethel CR, Gootz TD, Shang W, Stroh J, Lau W, McLeod D, Price L, Marfat A, Distler A, Drawz SM, Chen H, Harry E, Nottingham M, Carey PR, Buynak JD, Bonomo RA.

Biochem Pharmacol. 2012 Feb 15;83(4):462-71. doi: 10.1016/j.bcp.2011.11.015. Epub 2011 Dec 2.

14.

Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, Vanscoy B, Defiglio H, Fikes S, Brown D, Drawz SM, Kulawy R, Louie A.

Antimicrob Agents Chemother. 2012 Jan;56(1):231-42. doi: 10.1128/AAC.05252-11. Epub 2011 Oct 17.

15.

Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.

Drawz SM, Taracila M, Caselli E, Prati F, Bonomo RA.

Protein Sci. 2011 Jun;20(6):941-58. doi: 10.1002/pro.612. Epub 2011 May 3.

16.

Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy.

Nottingham M, Bethel CR, Pagadala SR, Harry E, Pinto A, Lemons ZA, Drawz SM, Akker Fv, Carey PR, Bonomo RA, Buynak JD.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):387-93. doi: 10.1016/j.bmcl.2010.10.134. Epub 2010 Nov 5.

17.

Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.

Ke W, Sampson JM, Ori C, Prati F, Drawz SM, Bethel CR, Bonomo RA, van den Akker F.

Antimicrob Agents Chemother. 2011 Jan;55(1):174-83. doi: 10.1128/AAC.00930-10. Epub 2010 Nov 1.

18.

Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase.

Bou G, Santillana E, Sheri A, Beceiro A, Sampson JM, Kalp M, Bethel CR, Distler AM, Drawz SM, Pagadala SR, van den Akker F, Bonomo RA, Romero A, Buynak JD.

J Am Chem Soc. 2010 Sep 29;132(38):13320-31. doi: 10.1021/ja104092z.

19.

Penicillin sulfone inhibitors of class D beta-lactamases.

Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA.

Antimicrob Agents Chemother. 2010 Apr;54(4):1414-24. doi: 10.1128/AAC.00743-09. Epub 2010 Jan 19.

20.

Three decades of beta-lactamase inhibitors.

Drawz SM, Bonomo RA.

Clin Microbiol Rev. 2010 Jan;23(1):160-201. doi: 10.1128/CMR.00037-09. Review.

21.

Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MG, Drawz SM, Bonomo RA.

Biochemistry. 2010 Feb 9;49(5):1014-23. doi: 10.1021/bi9015549.

22.

Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Drawz SM, Babic M, Bethel CR, Taracila M, Distler AM, Ori C, Caselli E, Prati F, Bonomo RA.

Biochemistry. 2010 Jan 19;49(2):329-40. doi: 10.1021/bi9015988.

23.

The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Drawz SM, Bethel CR, Hujer KM, Hurless KN, Distler AM, Caselli E, Prati F, Bonomo RA.

Biochemistry. 2009 Jun 2;48(21):4557-66. doi: 10.1021/bi9003292.

24.

DNA dissociation and degradation at gold nanoparticle surfaces.

Herdt AR, Drawz SM, Kang Y, Taton TA.

Colloids Surf B Biointerfaces. 2006 Aug 15;51(2):130-9. Epub 2006 Jun 27.

PMID:
16879950

Supplemental Content

Support Center